Well Lead Medical Co., Ltd. (603309.SS)
- Previous Close
11.72 - Open
11.83 - Bid 11.74 x --
- Ask 11.75 x --
- Day's Range
11.62 - 11.89 - 52 Week Range
9.45 - 14.67 - Volume
3,956,920 - Avg. Volume
3,597,395 - Market Cap (intraday)
3.441B - Beta (5Y Monthly) --
- PE Ratio (TTM)
15.06 - EPS (TTM)
0.78 - Earnings Date --
- Forward Dividend & Yield 0.50 (4.27%)
- Ex-Dividend Date May 23, 2024
- 1y Target Est
--
Well Lead Medical Co., Ltd. engages in the development, production, and sale of medical devices in anaesthesia, urology, endourology, respiratory, pain management, and hemodialysis areas worldwide. It manufactures and sells urology products, including Foley catheter, Nelaton catheters, urine collection products, and accessories; endourology products, such as the ClearPetra family system, ureterorenoscope, guide wires, ureteral stent, and stone retrieval basket; anesthesia products, comprising endotracheal tubes, intubation accessories, laryngeal masks, endobronchial tubes, tracheostomy tubes, anesthesia breathing circuits and accessories, and nasopharyngeal and oropharyngeal airway products; respiratory products, including oxygen and aerosol therapy products, and capnography mask and cannula products; drainage/suction/gastroenterology products, such as drainage systems, Yankauer handles, suction catheters, and stomach and feeding tubes; hemodialysis blood tubing set; home care products, including male external catheter and Convicath intermittent catheter; and ambulatory infusion pump for pain management. The company was founded in 1998 and is headquartered in Guangzhou, China.
www.wellead.comRecent News: 603309.SS
View MorePerformance Overview: 603309.SS
Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 603309.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 603309.SS
View MoreValuation Measures
Market Cap
3.44B
Enterprise Value
3.48B
Trailing P/E
15.06
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.22
Price/Book (mrq)
1.77
Enterprise Value/Revenue
2.25
Enterprise Value/EBITDA
12.31
Financial Highlights
Profitability and Income Statement
Profit Margin
14.73%
Return on Assets (ttm)
6.17%
Return on Equity (ttm)
12.27%
Revenue (ttm)
1.55B
Net Income Avi to Common (ttm)
228.06M
Diluted EPS (ttm)
0.78
Balance Sheet and Cash Flow
Total Cash (mrq)
475.91M
Total Debt/Equity (mrq)
26.01%
Levered Free Cash Flow (ttm)
-20.26M